jannolta.bsky.social profile picture

Jan Nolta, PhD

@jannolta.bsky.social

1844 Followers

1733 Following

Director, Cell and Gene Therapy at University of California Davis Health in Sacramento. Editor of the journal Stem Cells. #Firstgen #celltherapy #stemcells #GeneTherapy

https://orcid.org/0000-0003-4576-8542

  1. jannolta.bsky.social profile picture

    Jan Nolta, PhD @jannolta.bsky.social

    The regime halted all federal grants then told UC administration if they pay $1 billion they could have them back. It’s like ransomware. UC is a public university system and we cannot do this. So, no grants = no research and labs will shut down. Are we great yet?

    dailybruin.com/2025/08/09/a...

    Dr. Jerzy Kupiec-Weglinski has led organ transplant research at UCLA for nearly three decades. Kupiec-Weglinski, the vice chairman of basic science research in the David Geffen School of Medicine’s su...

    'An attack on knowledge': UCLA researchers say lifesaving research is in jeopardy - Daily Bruin

    Dr. Jerzy Kupiec-Weglinski has led organ transplant research at UCLA for nearly three decades. Kupiec-Weglinski, the vice chairman of basic science research in the David Geffen School of Medicine’s su...
    2
  2. jannolta.bsky.social profile picture

    Jan Nolta, PhD @jannolta.bsky.social

    The regime halted all federal grants then told UC administration if they pay $1 billion they could have them back. It’s like ransomware. UC is a public university system and we cannot do this. So, no grants = no research and labs will shut down. Are we great yet?

    dailybruin.com/2025/08/09/a...

    Dr. Jerzy Kupiec-Weglinski has led organ transplant research at UCLA for nearly three decades. Kupiec-Weglinski, the vice chairman of basic science research in the David Geffen School of Medicine’s su...

    'An attack on knowledge': UCLA researchers say lifesaving research is in jeopardy - Daily Bruin

    Dr. Jerzy Kupiec-Weglinski has led organ transplant research at UCLA for nearly three decades. Kupiec-Weglinski, the vice chairman of basic science research in the David Geffen School of Medicine’s su...
    2
  5. braithwaiteat.bsky.social profile picture

    Adam Braithwaite @braithwaiteat.bsky.social

    Stimulating immune cells in vitro is a common experimental lab model. We profiled 150K blood immune cells treated with 11 different stimuli to compare the effects. The data are freely available for researchers. See the preprint for our findings and to access the data 🧪 doi.org/10.1101/2025...

    9
  6. bllphd.bsky.social profile picture

    Bruce Levine, Ph.D. 🇺🇦 @bllphd.bsky.social

    Bioengineered immunocompetent preclinical trial-on-chip tool enables screening of CAR T cell therapy for leukaemia. #Tcell #immunotherapy #organonachip 🧪https://www.nature.com/articles/s41551-025-01428-2

    An ex vivo organotypic and immunocompetent human leukaemia chip system is used for CAR T cell therapy modelling and screening of patient response.

    Bioengineered immunocompetent preclinical trial-on-chip tool enables screening of CAR T cell therapy for leukaemia - Nature Biomedical Engineering

    An ex vivo organotypic and immunocompetent human leukaemia chip system is used for CAR T cell therapy modelling and screening of patient response.
    0
  7. kffhealthnews.org profile picture

    KFF Health News @kffhealthnews.org

    After spearheading a 34% cut in cancer mortality, the National Cancer Institute at the NIH is bleeding resources and staff and could see its budget cut by nearly 40%. kffhealthnews.org/news/article...

    After spearheading a 34% cut in cancer mortality, the National Cancer Institute at the NIH is bleeding resources and staff and could see its budget cut by nearly 40%.

    World’s Premier Cancer Institute Faces Crippling Cuts and Chaos - KFF Health News

    After spearheading a 34% cut in cancer mortality, the National Cancer Institute at the NIH is bleeding resources and staff and could see its budget cut by nearly 40%.
    0
  10. cellpress.bsky.social profile picture

    Cell Press @cellpress.bsky.social

    Reply to cellpress.bsky.social

    "Specific targeting of brain endothelial cells using enhancer AAV vectors" www.cell.com/neuron/fullt...

    Xiangmin Xu & colleagues @cp-neuron.bsky.social

    Velazquez-Rivera et al. have developed and validated a set of new BEC-enhancer AAV vectors that allow for selective genetic labeling of, and access to, brain endothelial cells (BECs). These useful too...

    Specific targeting of brain endothelial cells using enhancer AAV vectors

    Velazquez-Rivera et al. have developed and validated a set of new BEC-enhancer AAV vectors that allow for selective genetic labeling of, and access to, brain endothelial cells (BECs). These useful too...
    1